SP 600125

Drug Profile

SP 600125

Alternative Names: SP600125

Latest Information Update: 19 Dec 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Signal Research Division
  • Class Antirheumatics
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase 8 inhibitors; Mitogen-activated protein kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allotransplant rejection; Asthma; Cancer; Cerebral ischaemia; Rheumatoid arthritis

Most Recent Events

  • 05 Feb 2008 No development reported - Preclinical for Allotransplant rejection in USA (unspecified route)
  • 05 Feb 2008 No development reported - Preclinical for Cerebral ischaemia in China (unspecified route)
  • 20 Oct 2005 Preclinical trials in Cerebral ischaemia in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top